Mantle Cell Lymphoma
This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory).
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa
- Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies
- Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study
- Varnimcabtagene autoleucel (ARI‑00001) in relapsed or refractory mantle cell lymphoma